The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

Rody, Achim; Karn, Thomas; Solbach, Christine; Gaetje, R.; Munnes, M.; Kissler, Stefan; Ruckhäberle, Eugen; Minckwitz, Gϋnter von; Loibl, Sibylle; Holtrich, Uwe; Kaufmann, M.

doi:10.1016/j.breast.2007.02.006

Cited by 54 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11][12] In our previous study of 359 cases, pathologic complete response was observed in 33% of ERÀ/PRÀ/HER2 þ cases, 30% of triple-negative cases and in o10% of ER þ cases. Among the ER þ tumors, pathologic complete response was predominantly seen in tumors that co-expressed HER2 with low-to-moderate ER expression.…”

mentioning

confidence: 85%

“…In these previous studies, including our previous study, most patients were treated with chemotherapy regimens that did not include trastuzumab. 9,11,13 This is because trastuzumab has been only rarely used in neoadjuvant chemotherapy regimens before 2006, where its use was limited to clinical trials (MD Anderson trial, NOAH trial and GeparQuattro trial). [14][15][16] Recently, trastuzumab is increasingly used preoperatively in HER2 þ breast carcinoma, often as TCH regimen (Taxoteres, carboplatinum, Herceptins) or as AC followed by TH (ie, adriamycin, cyclophosphamide followed by taxane and herceptin) or in some other combination.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

et al. 2011

View full text Add to dashboard Cite

Pathologic complete response to neoadjuvant chemotherapy without trastuzumab in hormone receptornegative/HER2 þ tumors is seen in 27-45% of cases. In contrast, estrogen receptor (ER) þ /HER2 þ tumors demonstrate pathologic complete response in B8% of cases and is generally limited to weak-to-moderate ER þ /HER2 þ tumors. It is speculated that addition of trastuzumab to neoadjuvant chemotherapy regimen will increase the pathologic complete response rates in all HER2 þ tumors. A list of HER2 þ patients who received neoadjuvant chemotherapy (with trastuzumab) in the years 2007-2010 was obtained from our hospital database. The 104 HER2 þ tumors were classified into three groups based on semiquantitative hormone receptor and HER2 results as follows: ERBB2 (ER-/PR-[H-score r10]/HER2 þ ), Luminal B-HER2 Hybrid (LBHH; weak to moderate ER þ [H-score 11-199]/HER2 þ ), and Luminal A-HER2 Hybrid (LAHH; strong ER þ [H-score Z200]/ HER2 þ ). Pathologic complete response was defined as absence of invasive carcinoma in the resection specimen and in the lymph nodes. Percentage tumor volume reduction was also calculated based on pretherapy size and detailed evaluation of the resection specimen. In all, 52% (25 of 48 cases) of ERBB2 tumors showed pathologic complete response, which was significantly higher than the pathologic complete response rate in LBHH (33%; 10 of 30) and LAHH (8%; 2 of 26) tumors. Average percentage tumor volume reduction was also highest in ERBB2 tumors (86%), followed by LBHH (74%) and LAHH (64%) tumors. We conclude that addition of trastuzumab to neoadjuvant chemotherapy regimen significantly increases the pathologic complete response rates in all HER2 þ tumors. However, the benefit of trastuzumab is highest in ER-negative tumors and progressively decreases with increase in tumor ER expression. This information can be utilized to counsel patients considered for neoadjuvant chemotherapy and the same principle could be applied in the adjuvant setting.

show abstract

mentioning

confidence: 85%

mentioning

confidence: 99%

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…We included 238 of our own samples (datasets Frankfurt, Frankfurt-2, and Frankfurt-3) which have been described previously (Ahr et al 2002 [9], [10], Rody et al 2008 [11], Ruckhäberle et al 2008 [12], and Rody et al 2007 [13], respectively) as well as 2792 samples from 22 different publicly available datasets (Table 1): Rotterdam [14][15][16], Mainz [17], Trans-BIG [18], Oxford-Untreated [19], London [20], London-2 [21], Oxford-Tamoxifen, Veridex-Tam [22], Stockholm [23], Uppsala [24,25], San Francisco [26], New York [27], MDA133 [28], EORTC [29], Edinburgh [30], ExpO [31], Signapore [32], Genentech [33], Boston [34], Berlin [35], Paris [36], and Tampa [37]. For comparability, only the ProbeSets from the Affymetrix HG-U133A microarray were used from seven datasets where HG-U133?…”

Section: Methodsmentioning

confidence: 99%

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Karn

Metzler

Ruckhäberle

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…triple negative) [2][3][4]. Although the normal breast-like cancers are still poorly characterised, they are reported to have a prognosis that is better than that of BLCs [3,23] and do not seem to respond to neoadjuvant chemotherapy [84,86]. In fact, in one study, 45% of patients with BLC showed pathological complete response following anthracycline + taxanes neoadjuvant chemotherapy, whereas none of the normal breast like cancers did so [84].…”

Section: Blc and Triple-negative Breast Cancermentioning

confidence: 99%

Patho-biological aspects of basal-like breast cancer

Rakha

El-Sayed

Reis‐Filho³

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer comprises a remarkably diverse group of diseases in terms of presentation, morphology, molecular profile and response to therapy. Recent gene expression profiling of breast cancer has identified specific molecular subtypes of clinical significance. Basal-like cancers (BLC) comprise a group of tumours that are characterised by an expression signature similar to that of the basal/myoepithelial cells of the breast and cluster together with BRCA1 associated tumours. Although BLC has fascinated oncologists and scientists alike due to its enigmatic clinical and pathological parameters, there is no consensus about the definition and method of identification in routine practice of this rather heterogeneous group of cancers. Furthermore, the prognostic significance of BLCs and response to specific chemotherapy regimens are still a matter debate. In this review, we discuss the molecular and morphological features, prognostic significance of BLC, and explore its impact on the concept of the breast cancer stem cell.

show abstract

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

Cited by 54 publications

References 16 publications

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Patho-biological aspects of basal-like breast cancer

Contact Info

Product

Resources

About